Profile data is unavailable for this security.
About the company
Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.
- Revenue in USD (TTM)2.82m
- Net income in USD-97.09m
- Incorporated2018
- Employees44.00
- LocationPyxis Oncology Inc321 Harrison AvenueBOSTON 02118United StatesUSA
- Phone+1 (617) 221-9059
- Fax+1 (302) 655-5049
- Websitehttps://pyxisoncology.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spruce Biosciences Inc | 697.00k | -47.88m | 70.95m | 9.00 | -- | 6.94 | -- | 101.80 | -84.64 | -84.64 | 1.22 | 9.56 | 0.0173 | -- | -- | 33,190.48 | -119.08 | -43.45 | -161.94 | -49.92 | -- | -- | -6,869.30 | -1,459.77 | -- | -353.48 | 0.091 | -- | -51.32 | -- | -10.68 | -- | -- | -- |
| Maia Biotechnology Inc | 0.00 | -22.34m | 71.10m | 13.00 | -- | 1,587.38 | -- | -- | -0.7504 | -0.7504 | 0.00 | 0.0012 | 0.00 | -- | -- | 0.00 | -212.50 | -208.29 | -602.02 | -373.18 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -17.61 | -- | -- | -- |
| Medicinova Inc | 257.92k | -12.01m | 72.74m | 13.00 | -- | 1.65 | -- | 282.01 | -0.2449 | -0.2449 | 0.0053 | 0.8964 | 0.0049 | -- | -- | 19,840.00 | -22.73 | -15.56 | -24.08 | -16.17 | -- | -- | -4,656.61 | -1,144.98 | -- | -- | 0.00 | -- | -100.00 | -- | -28.91 | -- | -39.68 | -- |
| XBiotech Inc | 0.00 | -29.16m | 74.69m | 88.00 | -- | 0.4471 | -- | -- | -0.9566 | -0.9566 | 0.00 | 5.48 | 0.00 | -- | -- | 0.00 | -15.25 | -7.74 | -16.08 | -8.02 | -- | -- | -- | -187.68 | -- | -- | 0.00 | -- | -- | -- | -56.90 | -- | 44.92 | -- |
| Seres Therapeutics Inc | 351.00k | 5.39m | 76.62m | 103.00 | 14.38 | 1.70 | 7.93 | 218.30 | 0.5892 | 0.5892 | 0.0404 | 4.99 | 0.0022 | -- | -- | 3,407.77 | 3.35 | -42.44 | 4.59 | -55.22 | -- | -- | 1,536.75 | -367.23 | -- | -- | 0.00 | -- | -- | -- | 33.85 | -- | -17.63 | -- |
| Ibio Inc | 500.00k | -20.11m | 76.69m | 20.00 | -- | 0.8024 | -- | 153.37 | -1.44 | -1.44 | 0.0232 | 2.77 | 0.0113 | -- | 15.38 | 25,000.00 | -45.35 | -30.90 | -50.81 | -37.76 | -- | -- | -4,021.60 | -2,374.12 | -- | -- | 0.0127 | -- | 77.78 | -24.57 | -19.00 | -- | -57.50 | -- |
| Nuo Therapeutics Inc | 2.61m | -2.43m | 77.25m | -- | -- | -- | -- | 29.58 | -0.0517 | -0.0517 | 0.0555 | -0.0088 | 1.43 | 4.19 | 5.32 | -- | -133.29 | -121.45 | -289.99 | -243.05 | 70.38 | 78.52 | -93.06 | -424.19 | 1.00 | -17,110.33 | -- | -- | 124.34 | 56.34 | 26.73 | -- | -- | -- |
| ImageneBio Inc | 0.00 | -46.14m | 77.27m | 15.00 | -- | 0.5526 | -- | -- | -8.11 | -8.11 | 0.00 | 12.51 | 0.00 | -- | -- | 0.00 | -29.23 | -29.58 | -31.29 | -33.67 | -- | -- | -- | -407.25 | -- | -- | 0.00 | -- | -100.00 | -- | 27.77 | -- | -- | -- |
| Tenax Therapeutics Inc | 0.00 | -43.33m | 78.98m | 4.00 | -- | 0.7767 | -- | -- | -1.13 | -1.13 | 0.00 | 16.29 | 0.00 | -- | -- | 0.00 | -42.77 | -99.65 | -44.80 | -118.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -128.28 | -- | -- | -- |
| TuHURA Biosciences Inc | 0.00 | -43.77m | 80.76m | 19.00 | -- | 4.13 | -- | -- | -1.60 | -1.60 | 0.00 | 0.3273 | 0.00 | -- | -- | 0.00 | -286.97 | -- | -456.76 | -- | -- | -- | -- | -- | -- | -9.01 | 0.0286 | -- | -- | -- | -- | -- | -- | -- |
| Pyxis Oncology Inc | 2.82m | -97.09m | 80.94m | 44.00 | -- | 1.17 | -- | 28.70 | -1.58 | -1.58 | 0.0457 | 1.11 | 0.0187 | -- | -- | 64,090.91 | -64.53 | -47.22 | -74.33 | -53.45 | 0.00 | -- | -3,442.77 | -2,233.63 | -- | -- | 0.0006 | -- | -- | -- | -4.80 | -- | -- | -- |
| Champions Oncology Inc | 58.42m | 2.49m | 84.43m | 213.00 | 36.48 | 20.25 | 21.23 | 1.45 | 0.1667 | 0.1667 | 4.14 | 0.3003 | 2.11 | -- | 5.31 | 274,291.10 | 8.78 | -4.67 | 33.91 | -11.66 | 50.11 | 47.28 | 4.16 | -2.79 | -- | -- | 0.0327 | -- | 13.54 | 12.13 | 164.61 | -- | -29.41 | -- |
| eXoZymes Inc | 0.00 | -8.34m | 85.87m | 31.00 | -- | 15.95 | -- | -- | -1.76 | -1.76 | 0.00 | 0.6408 | 0.00 | -- | -- | 0.00 | -147.87 | -- | -393.50 | -- | -- | -- | -- | -- | -- | -- | 0.0217 | -- | -- | -- | -187.55 | -- | -- | -- |
| aTyr Pharma Inc | 190.00k | -75.12m | 87.59m | 56.00 | -- | 1.09 | -- | 461.00 | -0.8345 | -0.8345 | 0.0021 | 0.8188 | 0.0019 | -- | 0.1323 | 3,392.86 | -75.78 | -47.98 | -88.99 | -54.91 | -- | -- | -39,540.53 | -978.90 | -- | -- | 0.0127 | -- | -33.43 | -11.05 | -27.06 | -- | -3.83 | -- |
| Biomea Fusion Inc | 0.00 | -95.71m | 88.38m | 42.00 | -- | 4.76 | -- | -- | -2.39 | -2.39 | 0.00 | 0.2625 | 0.00 | -- | -- | 0.00 | -115.59 | -62.24 | -156.30 | -68.84 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -18.06 | -- | -- | -- |
| Precision BioSciences Inc | 698.00k | -83.60m | 89.07m | 67.00 | -- | 2.83 | -- | 127.61 | -8.40 | -8.40 | 0.0695 | 1.38 | 0.0057 | -- | 0.9001 | 6,462.96 | -67.76 | -26.22 | -76.07 | -33.68 | -- | -- | -11,977.36 | -87.80 | -- | -190.84 | 0.5736 | -- | 40.98 | 25.30 | 116.85 | -- | -59.31 | -- |
Data as of Feb 13 2026. Currency figures normalised to Pyxis Oncology Inc's reporting currency: US Dollar USD
29.59%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Laurion Capital Management LPas of 31 Dec 2025 | 4.80m | 7.70% |
| Gordonmd Global Investments LPas of 14 Jul 2025 | 3.83m | 6.16% |
| Tang Capital Management LLCas of 30 Sep 2025 | 2.50m | 4.02% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.01m | 3.23% |
| Perceptive Advisors LLCas of 30 Sep 2025 | 1.18m | 1.89% |
| Palo Alto Investors LPas of 30 Sep 2025 | 1.04m | 1.67% |
| Millennium Management LLCas of 30 Sep 2025 | 815.33k | 1.31% |
| Jane Street Capital LLCas of 31 Dec 2025 | 786.01k | 1.26% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 733.85k | 1.18% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 728.38k | 1.17% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
